TY  - CHAP
M1  - Book, Section
TI  - Subcutaneous amivantamab with lazertinib is non-inferior to intravenous administration, with fewer adverse reactions
A1  - Giuliano, Vanessa
A1  - Chan, Sze Wah Samuel
Y1  - 2015
N1  - 
T2  - 2 Minute Medicine
AB  - 
SN  - 
PB  - McGraw Hill
CY  - New York, NY
Y2  - 2024/10/15
UR  - accessmedicine.mhmedical.com/updatesContent.aspx?gbosid=649041
ER  -